Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1–6 without cirrhosis

Paul Y. Kwo, Fred Poordad, Armen Asatryan, +19

Journal of Hepatology

Diagnostic VirologyHepatologyHepatitis CViral HepatitisImmunology +7

Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis

Tarik Asselah, Kris V. Kowdley, Neddie Zadeikis, +19

Clinical Gastroenterology and Hepatology

Glecaprevir/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and/or prior treatment experience: A partially randomized phase 3 clinical trial

David Wyles, Fred Poordad, Stanley Wang, +14

Hepatology

High Efficacy of ABT-493 and ABT-530 Treatment in Patients With HCV Genotype 1 or 3 Infection and Compensated Cirrhosis

Edward Gane, Fred Poordad, Stanley Wang, +12

Gastroenterology

HepatologyHepatitis CViral HepatitisLiver PhysiologyCompensated Cirrhosis +6

A complex epistatic network limits the mutational reversibility in the influenza hemagglutinin receptor-binding site

Nicholas C. Wu, Andrew J. Thompson, Jia Xie, +6

Nature Communications

EngineeringReverse GeneticsImmunologyViral PathogenesisMolecular Biology +14

Preventing an Antigenically Disruptive Mutation in Egg-Based H3N2 Seasonal Influenza Vaccines by Mutational Incompatibility

Nicholas C. Wu, Huibin Lv, Andrew J. Thompson, +10

Cell Host & Microbe

GeneticsImmunologyMolecular BiologyAntigenically Disruptive MutationFlu Vaccination +16

Potent Antiviral Activities of the Direct-Acting Antivirals ABT-493 and ABT-530 with Three-Day Monotherapy for Hepatitis C Virus Genotype 1 Infection

Eric Lawitz, William O’Riordan, Armen Asatryan, +10

Antimicrobial Agents and Chemotherapy

Hcv Ns5a InhibitorImmunologyPharmacotherapyAntiviral DrugAutoimmune Liver Disease +16

A cell–cell interaction format for selection of high-affinity antibodies to membrane proteins

Zhuo Yang, Yue Wan, Pingdong Tao, +6

Proceedings of the National Academy of Sciences

Safety and Pharmacokinetics of Glecaprevir/Pibrentasvir in Adults With Chronic Genotype 1–6 Hepatitis C Virus Infections and Compensated Liver Disease

Edward Gane, Fred Poordad, Neddie Zadeikis, +16

Clinical Infectious Diseases

Efficacy and Pharmacokinetics of Glecaprevir and Pibrentasvir With Concurrent Use of Acid-Reducing Agents in Patients With Chronic HCV Infection

Steven L. Flamm, K. Rajender Reddy, Neddie Zadeikis, +13

Clinical Gastroenterology and Hepatology